What should the investigator provide to the sponsor, the IRB/IEC, and regulatory authority for reported deaths when available?

Boost your GCP E6 (R3) exam readiness. Improve your understanding with engaging, insightful questions. Test yourself with hints and detailed explanations. Prepare effectively!

Multiple Choice

What should the investigator provide to the sponsor, the IRB/IEC, and regulatory authority for reported deaths when available?

When a death occurs in a clinical trial, the investigator plays a key role in safety oversight by supplying information to those overseeing the study. The best practice is to provide the sponsor, the IRB/IEC, and regulatory authorities with any additional information that is requested, such as autopsy reports and terminal medical reports, when available. Autopsy findings can clarify the exact cause of death and reveal any pathological factors or links to the investigational product, while terminal medical reports offer a detailed timeline of clinical events leading to death. This information supports accurate causality assessment and appropriate risk management. If such documents are available, they should be shared promptly; if not, share all other pertinent data you have. The other options underestimate the need for thorough safety information or dismiss the relevance of autopsy data, which is often crucial for proper safety evaluation.

When a death occurs in a clinical trial, the investigator plays a key role in safety oversight by supplying information to those overseeing the study. The best practice is to provide the sponsor, the IRB/IEC, and regulatory authorities with any additional information that is requested, such as autopsy reports and terminal medical reports, when available. Autopsy findings can clarify the exact cause of death and reveal any pathological factors or links to the investigational product, while terminal medical reports offer a detailed timeline of clinical events leading to death. This information supports accurate causality assessment and appropriate risk management. If such documents are available, they should be shared promptly; if not, share all other pertinent data you have. The other options underestimate the need for thorough safety information or dismiss the relevance of autopsy data, which is often crucial for proper safety evaluation.

More practice questions